ImmunityBio Secures $100M Financing, Including $75M Non-Dilutive Capital, Amidst Global ANKTIVA Approvals

summarizeSummary

ImmunityBio announced $100 million in new financing, comprising a $75 million non-dilutive revenue interest purchase and a $25 million debt-to-equity conversion by an affiliate of its Executive Chairman, significantly strengthening its balance sheet and supporting global expansion following recent ANKTIVA approvals.

check_boxKey Events

• $75M Non-Dilutive Financing Secured

  ImmunityBio entered a Second Amendment to its Revenue Interest Purchase Agreement, securing an additional $75 million through the sale of revenue interests to Oberland Capital. This increases total committed capital under the agreement to $375 million, with proceeds designated for general corporate purposes, including advancing regulatory approval efforts, pre-commercialization activities, and clinical development programs.

• $25M Debt-to-Equity Conversion by Affiliate

  Nant Capital, an entity affiliated with Executive Chairman Dr. Patrick Soon-Shiong, converted $25 million of outstanding convertible promissory notes into 4,606,596 shares of common stock. This transaction reduces the company's debt and strengthens its balance sheet, though it is dilutive to existing shareholders.

• Global ANKTIVA Approvals Highlighted

  The financing announcement was accompanied by news of recent global regulatory approvals for ANKTIVA in five jurisdictions: the U.S. (April 2024), UK (July 2025), Saudi Arabia (January 2026, including for lung cancer), European Union (February 2026), and Macau (March 2026), significantly expanding its market footprint.

auto_awesomeAnalysis

This filing details a crucial $100 million financing package for ImmunityBio, providing substantial capital for its commercialization efforts and pipeline advancement. The $75 million non-dilutive revenue interest purchase, representing a significant capital infusion, provides immediate cash while the $25 million debt-to-equity conversion by an affiliated entity reduces liabilities, albeit with some dilution. This capital infusion is particularly impactful as it follows a recent FDA warning letter, offering a strong positive counter-signal. Furthermore, the accompanying press release highlights a series of major global regulatory approvals for ANKTIVA across five jurisdictions, including a first-ever authorization for lung cancer in Saudi Arabia, underscoring the company's strong product development momentum and expanding market reach. Investors should view this as a significant step in securing financial stability and advancing its key immunotherapy product globally.